REP 2139-Mg + nucleos(t)ide analogue

REP 2139-Mg + nucleos(t)ide analogue is an investigational combination therapy developed by Replicor for the treatment of chronic Hepatitis B (HBV) and Hepatitis D (HDV) infections. The combination consists of REP 2139-Mg, a nucleic acid polymer (NAP) formulated as a magnesium chelate complex, and a nucleos(t)ide analogue (NUC) partner such as tenofovir disoproxil fumarate (TDF). REP 2139-Mg acts as a sequence-independent phosphorothioate oligonucleotide that targets the host chaperone DNAJB12, preventing the proper folding and assembly of hepatitis B virus surface antigen (HBsAg) into subviral particles (SVPs), which clears circulating HBsAg. It also directly interacts with hepatitis delta antigen (HDAg) to inhibit HDV RNA replication and ribonucleoprotein (RNP) assembly. The addition of a NUC partner provides complementary inhibition of HBV reverse transcription. This combination therapy, administered subcutaneously, has demonstrated the potential to achieve functional cure of HBV and sustained virological response of HDV in clinical trials and compassionate access programs, particularly in patients with advanced liver disease or those who have failed prior therapies.

Other names

HBV/HDV programREP 2139-Mg (SC) - NUC combinationREP 2139-Mg + NUCREP 2139-Mg + TDFREP 2139-Mg + nucleos(t)ide analogueREP 2139-Mg + nucleoside analogueREP 2139-Mg + nucleotide analogueREP 2139-Mg + tenofovir disoproxil fumarate